dihydrophenethylamine | 125974-33-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dihydrophenethylamine
• 英文别名: Dihydrophenylethylamine；2-cyclohexa-2,4-dien-1-ylethanamine
• CAS: 125974-33-6
• 化学式: C₈H₁₃N
• 分子量: 123.198
• InChiKey: UMMSYUVOUOAZFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  dihydrophenethylamine 在 palladium diacetate 、 三乙胺 、 对苯醌 、 lithium chloride 作用下， 以 溶剂黄146 、 丙酮 为溶剂， 反应 2.0h， 生成 (3aS,5R,7aS)-5-Chloro-2,3,3a,4,5,7a-hexahydro-indole-1-carboxylic acid benzylamide
  参考文献：
  名称：

  Bäckvall, Jan-E.; Andersson, Pher G., Journal of the American Chemical Society, 1990, vol. 112, # 9, p. 3683 - 3685

  摘要：

  DOI：
• 作为产物：
  描述：

  Methanesulfonic acid 2-cyclohexa-2,4-dienyl-ethyl ester 在 氢气 、 potassium phtalimide 、 肼 作用下， 生成 dihydrophenethylamine
  参考文献：
  名称：

  Bäckvall, Jan-E.; Andersson, Pher G., Journal of the American Chemical Society, 1990, vol. 112, # 9, p. 3683 - 3685

  摘要：

  DOI：

文献信息

• 4,5-Disubstituted-1-aminoalkyl cyclohexenes
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04131744A1

  公开（公告）日：1978-12-26

  Compounds of the formula ##STR1## wherein R is hydrogen, ##STR2## R.sub.1 and R.sub.2 are independently selected from hydrogen, lower alkyl, and cycloalkyl or R.sub.1 and R.sub.2 taken together with the nitrogen atom to which they are attached form a ring of the formula ##STR3## N IS 0 OR AN INTEGER FROM 1 TO 3; M IS AN INTEGER FROM 1 TO 3; R.sub.3 and R.sub.4 are independently selected from hydrogen and lower alkyl; X is hydrogen, halogen, lower alkyl, lower alkoxy, or nitro; and their salts; are disclosed. These compounds possess useful antiinflammatory properties.

  该公式化合物为 ##STR1## 其中R为氢，##STR2## R.sub.1 和 R.sub.2 独立选择自氢、较低烷基和环烷基，或R.sub.1 和 R.sub.2 与它们连接的氮原子一起形成 ##STR3## 的环；N为0或1到3之间的整数；M为1到3之间的整数；R.sub.3 和 R.sub.4 独立选择自氢和较低烷基；X为氢、卤素、较低烷基、较低烷氧基或硝基；及其盐；已被披露。这些化合物具有有用的抗炎性能。
• C-MET MODULATORS AND METHODS OF USE
  申请人：Exelixis, Inc.

  公开号：EP3329918A2

  公开（公告）日：2018-06-06

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了调节蛋白激酶酶活性的化合物，用于调节细胞活动，如增殖、分化、细胞程序性死亡、迁移和化学侵袭。更具体地说，本发明提供了抑制、调节和/或调控激酶受体（尤其是 c-Met、KDR、c-Kit、flt-3 和 flt-4）的喹唑类和喹啉类化合物、与上述细胞活动变化有关的信号转导通路、含有这些化合物的组合物以及使用它们治疗激酶依赖性疾病和病症的方法。本发明还提供了制造上述化合物的方法，以及含有这些化合物的组合物。
• US4131744A
  申请人：——

  公开号：US4131744A

  公开（公告）日：1978-12-26
• US4149001A
  申请人：——

  公开号：US4149001A

  公开（公告）日：1979-04-10
• [EN] PEPTIDES FOR TREATMENT OF OBESITY<br/>[FR] PEPTIDES POUR LE TRAITEMENT DE L'OBÉSITÉ
  申请人：NOVO NORDISK AS

  公开号：WO2011104379A1

  公开（公告）日：2011-09-01

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.